Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
MoonLake Immunotherapeutics (MLTX) Stock Price & Analysis
296 Followers
MLTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.31 - $64.98
Previous Close$39.75
Volume404.25K
Average Volume (3M)452.06K
Market Cap
$2.54B
Enterprise Value$2.05B
Total Cash (Recent Filing)$511.01M
Total Debt (Recent Filing)$3.70M
Price to Earnings (P/E)-53.0
Beta0.83
Next Earnings
Aug 08, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding63,869,904
10 Day Avg. Volume265,235
30 Day Avg. Volume452,061
Standard Deviation0.22
R-Squared0.09
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-52.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-86.14
Forecast
1Y Price Target
$74.09Price Target Upside86.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
MoonLake Immunotherapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressSonelokimab has begun its pivotal trial program, showcasing a strong foundation based on successful earlier phase results and signaling potential as a preferred treatment option.
Financial HealthMoonLake's robust financial standing, with a significant cash reserve, ensures its operational funding through end of 2026, allowing for ongoing investment in product development and trials.
Market OpportunityWith the projected market size for treated conditions expected to reach over $10 billion by 2035, MoonLake's sonelokimab is poised to capture substantial market share, given its best-in-class treatment potential.
Bears Say
Competitive LandscapeThe competitive landscape in hidradenitis suppurativa is evolving with recent clinical updates from other major pharmaceutical players.
Financial OutlookThe lack of catalysts for rest of the year and MLTX not prioritizing a partnership prior to Ph. 3 data means little upside for the stock in 2024.
Market DifferentiationAnalyst did not see any convincing evidence of SLK’s differentiation in a very crowded and efficacious PsA market.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $24.31 and its highest was $64.98 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
Currently, no data Available
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 81 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on May 07, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.193 by -$0.027.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -$0.27.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 62,874,638 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.193. Following the earnings report the stock price went down -1.932%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Among the largest hedge funds holding MoonLake Immunotherapeutics’s share is Woodline Partners LP. It holds MoonLake Immunotherapeutics’s shares valued at 7M.
---
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.09 (86.39% Upside)
$74.09 (86.39% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.15%
12-Months-Change
Fundamentals
Return on Equity
-13.92%
Trailing 12-Months
Asset Growth
744.53%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
Helix Acquisition Corp is a blank check company.
---
MLTX Stock 12 Month Forecast
Average Price Target
$74.09
▲(86.39% Upside)
Technical Analysis
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+124.95%
reiterated a buy rating 12 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +124.95% per trade.
---